All In Biotech

Free tool

FAERS Monitor: Orfadin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021232 or its brand name (Orfadin, Nitisinone). Reports on generic versions are filed under their own applications.

Reports

820

Serious

649

79% of reports

Hospitalization

266

Death reported

146

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • amino acid level increased128
  • liver transplant117
  • hepatocellular carcinoma61
  • alpha 1 foetoprotein increased52
  • treatment noncompliance49
  • cataract47
  • hepatic failure44
  • hepatic cirrhosis37
  • death35
  • lenticular opacities34
  • succinylacetone increased33
  • vomiting33
  • off label use29
  • abdominal pain27
  • drug ineffective24

Reports by year received

View as table
YearReports
20046
20055
200611
20077
200814
200918
201020
201128
201237
201314
201412
201530
201651
201769
201899
2019129
2020112
202140
202251
202319
202418
202516
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,339 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
succinylacetone increasedSignal33282422.886787.7753,301
amino acid level increasedSignal1285343.74473.8561,553
lenticular opacitiesSignal342166.11536.765,874
alpha 1 foetoprotein increasedSignal522022.91538.295,548
liver transplantSignal117852.9718.995,550
hepatocellular carcinomaSignal61207.4162.812,230
hepatic cirrhosisSignal3750.636.91,749
hepatic failureSignal4437.528.11,526
treatment noncomplianceSignal4923.017.51,011
cataractSignal4720.315.3843
abdominal painSignal273.02.134
vomiting331.81.311
death351.00.80
off label use290.80.61
drug ineffective240.50.315

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.